An International Reputation for Cardiac Excellence
Stanford is recognized worldwide as a pioneering center for heart transplants. Dr. Norman Shumway and his colleagues developed the experimental basis for transplants in their early work, which then paved the way for the first adult heart transplant in the U.S. at Stanford in 1968. To date, our medical teams have performed more than 1,200 heart transplants.
Our multidisciplinary program includes:
Specialists in heart failure management and heart transplantation
Experts in cardiothoracic surgery
State-of-the-art diagnostic tests from radiologists, molecular biologists and pathologists
Access to new clinical trials in heart failure and heart transplantation
Innovations introduced in the transplant field from Stanford include:
The operative method for heart transplantation
The use of percutaneous, transvenous biopsy of the heart to detect rejection
The use of new immunosuppressive drugs, including cyclosporine, to prevent rejection
The first successful heart-lung transplantation procedure
The use of peripheral blood gene expression testing to identify patients at low risk for rejection, allowing doctors to safely decrease the number of biopsies performed
Approximately 40 to 50 patients undergo heart transplantation each year at Stanford. The procedures are performed in patients from newborns to adults over 60 years of age. Almost every type of end-stage heart disease has been treated here, and the Stanford team remains a leader in introducing new concepts and treatments to improve outcomes for transplant patients.
Now is the right time to start paying attention to your heart health. You can lower your risk for heart attack and stroke by knowing the risk factors that affect your heart.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.